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Acceptability of Behavioral Treatments
for Insomnia
Daniel Bluestein, MD, MS, CMD, AGSF, Amanda C. Healey, PhD, LPC-MHSP, NCC,
and Carolyn M. Rutledge, PhD, FNP-BC
Background: Behavioral treatments for insomnia are safe and efficacious but may not be embraced by
patients in primary care. Understanding factors associated with acceptability can enhance successful use
of these modalities. The objective of this study was to identify demographic and clinical/psychosocial
correlates of behavioral insomnia treatment acceptability.
Methods: This nonexperimental, inventory-based, cross-sectional study enrolled patients from a hos-
pital-sponsored primary care clinic and 2 urban academic family practices. Participants (n 236) were
18 years of age or older who had clinically significant insomnia (Insomnia Severity Index score> 8)
and were recruited consecutively at these sites. A study coordinator obtained informed consent then
distributed survey materials. Participants received a $10 honorarium. The main outcome measure was
the Acceptability Insomnia Treatment Acceptability Scale-Behavioral subscale (ITAS-B).
Results: Only acceptability of medications (r 0.259) and dysfunctional beliefs (r 0.234) scores
had significant bivariate correlations with ITAS-B scores (P< .001). Medication acceptability, dysfunc-
tional beliefs, and self-efficacy accounted for 12.45% of ITAS-B variance in linear regression.
Conclusions: Screening for dysfunctional beliefs about sleep may identify patients with interest in
behavioral approaches. Improving self-efficacy for sleep may improve acceptance of behavioral insom-
nia therapies. Interest in behavioral and medication treatments are not mutually exclusive. However,
the modest variance reported here suggests other factors impact acceptance of behavioral treatments.
(J Am Board Fam Med 2011;24:272–280.)
Keywords: Insomnia, Patient Acceptance of Health Care, Primary Health Care
Primary care clinicians prioritize disorders that are
common, costly, and severe. Placed in this perspec-
tive, insomnia is an important primary care con-
cern.1 An estimated 40 to 70 million Americans are
affected with insomnia intermittently, and 10% to
20% have chronic insomnia.2 Insomnia costs ex-
ceed $42 billion each year.3 Consequences include
mood disturbances, medication habituation, mem-
ory impairment, daytime fatigue, vocational and
interpersonal difficulties, increased health care uti-
lization, impaired health status,4–6 and accidents.7
Insomnia is often treated with hypnotic medica-
tions,8 Although indicated for the short term,9
medication usage may become chronic.10–12 Seda-
tion, abuse, physical and psychological dependence,
rebound insomnia,13 falls, and motor vehicle acci-
dents14,15 are potential sequelae. Newer agents
have less abuse potential16 but are costly ($100 to
$150 per month)17,18 and predispose the individual
to daytime sedation, psychological habituation, and
accidents.19
Concerns about drug treatments have fostered
interest among primary care clinicians in behav-
ioral interventions for insomnia. Evidence-based
techniques include stimulus control, relaxation,
sleep restriction, paradoxical intent, sleep hygiene,
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and cognitive-behavioral therapy.20,21 Compared
with medications, which are symptomatic treat-
ments, behavioral approaches lead to sustained
benefit because they address perpetuating behav-
iors and beliefs.22 Further advantages compared
with medications include no known side effects.
Nonetheless, patients may not embrace behav-
ioral treatments. Some may perceive receiving a
behavioral treatment as evidence of having a psy-
chiatric disorder. Such views may be associated
with poverty, lack of formal education, and racial or
ethnic minority status,23–25 perhaps because stig-
matization of treatments for “mental illness” is
more likely among these groups.26–29 Conversely,
demographic predictors of acceptance include fe-
male sex and higher educational attainment.30 Ef-
fects of age are unclear; some studies show positive
orientation and others negative.31
Behavioral treatments also require effort from a
motivated patient. Several clinical and psychosocial
variables may impact this motivation. Impaired
health status has been shown to forecast drop-out
from behavioral treatment programs for insom-
nia.32 Depression has been identified with reduced
adherence and impaired response to cognitive-be-
havioral therapy for insomnia.33 Self-efficacy for
sleep is another potential predictor because high
self-efficacy predicts readiness to undertake behav-
ioral change, whereas low self-efficacy points to a
lack of readiness to take action.34 Distorted beliefs
and attitudes concerning insomnia may accentuate
anxiety about not sleeping, and thus patients desire
rescue by medications.35 Insomnia severity has po-
tential import as a mediator of the urgency of
help-seeking.36,37
It is not known which of these demographic and
clinical/psychosocial predictors have greatest sa-
lience. Understanding which are most strongly as-
sociated with acceptability, or its lack, can enhance
successful use of behavioral treatments. Specifi-
cally, knowing how relationships vary across so-
ciodemographic subgroups can direct educational
interventions toward groups with lower interest.
Preferences for drug therapy would suggest a need
for education about risks and benefits of drugs as
well as the availability of nondrug alternatives. If
poor health status predicts low interest, then self-
rated health or other short health status question-
naires could screen for readiness to use behavioral
modalities. Depression, if predominant, can be
treated before or concurrently with the introduc-
tion of behavioral insomnia approaches. Motiva-
tional interviewing strategies would be indicated
should low self-efficacy be a net predictor of low
acceptance. Elicitation of dysfunctional beliefs and
attitudes about sleep may inform educational ap-
proaches. If insomnia severity mediates acceptance,
then assessment of severity could help select pa-
tients who are motivated to use behavioral or mixed
treatment modalities. Accordingly, this study was
undertaken to identify individual and net demo-
graphic and clinical/psychosocial correlates of be-




This nonexperimental, inventory-based, cross-sec-
tional study assessed relationships between the will-
ingness to engage in behavioral intervention for the
treatment of insomnia and demographic factors,
acceptability of medications, health status, depres-
sion, self-efficacy for sleep, dysfunctional beliefs
about sleep, and insomnia severity. Methods for
this study closely parallel those detailed in a related
article concerning psychosocial correlates of in-
somnia severity, which was previously published in
The Journal of the American Board of Family Medi-
cine.38 Accordingly, key elements are summarized
here, as are details about measures of treatment
acceptability, which were not reported previously.
Participants
Participants were recruited consecutively from pa-
tients 18 years of age or older who were seen for
care (any reason; not confined to seeking care for
sleep problems) at 3 clinical sites. These included a
hospital-sponsored primary care clinic (site 1) and 2
urban, academic family practice centers (sites 2 and
3). The study was advertised by flyers posted in
waiting rooms and examination rooms. Exclusion-
ary criteria included being younger than 18, being
illiterate, or lacking the cognitive capacity to com-
plete informed consent or respond to surveys. In-
clusion criteria entailed being age 18 or older and
having clinically significant insomnia, as indicated
by a score of 8 on the Insomnia Severity Index
(ISI). This is a 7-item questionnaire that asks re-
spondents to rate severity of recent problems with
sleep onset, sleep maintenance, early waking, and
impact of insomnia using a 5-point Likert scale
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(0  not at all, 4  extremely). ISI scores may
range from 0 to 28. Higher scores indicate more
severe insomnia, within 4 categories: absence of
insomnia (0–7), mild insomnia (8–14), moderate
insomnia (15–21), and severe insomnia (22–28).39
Data Collection
After the approval of the study by the institutional
review board, a study coordinator (ACH) obtained
informed consent then distributed survey packets
to participants. Surveys took between 20 to 30
minutes to complete. The coordinator was avail-
able to provide clarification if requested. Partici-
pants received a $10 cash honorarium after com-
pletion. Surveys were then stored without names or
other means of personal identification. Data were
entered and stored in a secure, password-protected
database accessible only to members of the research
team.
Measures
Treatment preferences were measured using the
Insomnia Treatment Acceptability Scale (ITAS).40
The ITAS describes 2 equally effective treatment
options. The first is a nondrug treatment method
aimed at teaching self-management approaches to
improving sleep. The other is a new medication (no
drug is named) to reduce physiologic and cognitive
arousal and to reduce nighttime awakening. Respon-
dents rate each treatment on identically worded,
8-item subscales (behavioral [ITAS-B] and medica-
tion [ITAS-M]), both of which are scored by visual
analog on a 100-mm line. Total score for each sub-
scale is the average of the 8 items, with higher scores
indicating greater willingness to utilize the treat-
ment. Reported Cronbach’s  values for the
ITAS-B and ITAS-M range from 0.80 to 0.87,
respectively.41,42 In this study, the Cronbach’s 
values were similar, being 0.859 and 0.861 for the
ITAS-B and ITAS-M, respectively. The ITAS-B is
used in this study to assess the outcome variable
(acceptability of behavioral sleep interventions).
The ITAS-M measures acceptability of medica-
tions as a potential predictor of behavioral accept-
ability.
Measured sociodemographic variables included
age, sex, race, marital status, and education. All
were assessed by a researcher-designed survey. Age
was measured as ratio (continuous) level data. Sex,
race, marital status, and educational level were cat-
egorical. Health status was measured with the
8-item Short Form (SF-8)43; depressive symptoms
were measured with the Center for Epidemiologic
Studies-Depression scale (CES-D)44; self-efficacy
was measured with the Self-Efficacy for Sleep scale
(SE-S)45; dysfunctional beliefs regarding sleep were
measured with the Dysfunctional Beliefs about
Sleep (DBAS) scale46,47; and insomnia severity was
measured with the ISI, as discussed above48 Reli-
ability and validity of these measures is detailed in
our earlier report.38
Statistical Analyses
Statistical analyses first entailed characterization of
participants using descriptive and summary statistics
(mean and SD for continuous variables; percentages
for categorical variables). Individual associations
with behavioral acceptability were examined us-
ing Pearson correlation coefficients for continu-
ous data and Spearman correlation coefficients for
ordinal data. All variables were screened for normality
before conducting analysis.Means were imputed for 5
cases that had less than 2 missing values on the
CES-D. Step-wise linear regression was then con-
ducted to provide an exploratory examination regard-
ing acceptability of medications, health status, depres-
sion, self-efficacy, dysfunctional beliefs, and insomnia
severity as net predictors of acceptability of behavioral
treatments.
Results
There were 236 participants: 163 from site 1, 56 from
site 2, and 17 from site 3. As shown in Table 1, mean
age was 45 years (range, 19–91 years), with 221
participants reporting. Participants were 74%
women (n  236), 74% African American (n 
160), and 36% were married (n  236). Of 235
participants reporting educational level, 64% re-
ported a high school education, 17% were college
graduates, and 19% reported postgraduate educa-
tion. Ten percent (30 participants) were age 65
years.
To obtain a significant effect size to achieve a
power level 0.80 while detecting at least a mod-
erate level of difference between correlated vari-
ables, an N  125 would be necessary to achieve
  0.01.49 This number was exceeded here, en-
suring adequate power to achieve practical signifi-
cance.
Table 2 reports means and SDs for the behavioral
treatment acceptability and psychosocial predictors
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according to site. Themean for behavioral acceptabil-
ity indicated above-average interest (ITAS-B mean,
0.65; range, 0.13–1.0), as did the mean for medication
acceptability (ITAS-M mean, 0.63; range, 0.04–
0.98). Means for psychosocial predictors were mid-
range for health status (SF-8 mean, 24; range, 8–42);
depression (CES-D mean, 22; range, 0–49); dys-
functional beliefs and attitudes about sleep
(DBAS mean, 0.50; range, 0.06–0.94); self-effi-
cacy (SE-S mean, 23; range, 9–45); and insomnia
severity (ISI mean, 17; range, 8–29).
As noted in Tables 1 and 2, there is no signifi-
cant variation by site with regard to sociodemo-
graphic attributes and means for the ITAS-B, ISI,
SF-8, CES-D, DBAS, and SE-S. Accordingly, data
were pooled for the subsequent regression analysis.
Table 3 reports individual correlation coeffi-
cients for independent variables with ITAS-B
scores (behavioral treatment acceptability). Spear-
man coefficients were computed for categorical
variables (sex, ethnicity, relationship status). Pear-
son coefficients were computed for interval/ratio
Table 1. Demographic Information
All Sites Site 1 Site 2 Site 3
Age, years (n  236)
Mean 45 45 44 45
Range 19–91 19–83 20–68 22–91
Sex (n  236)
Male 61 (26) 45 (28) 16 (29) 1 (6)
Female 175 (74) 118 (72) 40 (71) 16 (94)
Ethnicity (n  160)
African American 119 (74) 101 (73) 6 (60) 12 (71)
White 34 (21) 26 (20) 3 (30) 5 (29)
Asian 2 (1) 1 (1) 0 (0) 0 (0)
Hispanic 1 (0.5) 1 (1) 1 (10) 0 (0)
Other 4 (2.5) 4 (3) 0 (0) 0 (0)
Relationship status (n  236)
Married 84 (36) 56 (34) 19 (34) 9 (52)
Widowed 17 (7) 11 (7) 5 (9) 1 (6)
Never married 73 (31) 52 (32) 18 (32) 3 (18)
Divorced 62 (26) 44 (27) 14 (25) 4 (24)
Level of education (n  235)
Some high school 43 (18) 34 (21) 8 (14) 1 (6)
High school graduate 107 (46) 70 (43) 27 (48) 10 (58)
College graduate 40 (17) 26 (16) 10 (18) 4 (24)
Professional/graduate 45 (19) 32 (20) 11 (20) 2 (12)
Values provided as n (%), except for Age, which is presented as number of years.
Table 2. Means and Standard Deviations for Behavioral Acceptability and Psychosocial Predictors
Total Site 1 Site 2 Site 3
ITAS-B 0.65 (0.18) 0.65 (0.20) 0.67 (0.18) 0.66 (0.16)
ITAS-M 0.63 (0.18) 0.63 (0.18) 0.70 (0.15) 0.61 (0.19)
SF-8 24 (6.8) 24 (6.9) 24 (6.7) 23 (6.2)
CES-D 22 (11.2) 22 (11.2) 23 (11.6) 24 (9.8)
SE-S 23 (7.2) 24 (7.4) 22 (6.1) 22 (8.9)
DBAS 0.50 (0.15) 0.51 (0.16) 0.50 (0.14) 0.52 (0.14)
ISI 17 (5.4) 16 (5.4) 20 (4.2) 17 (7.2)
ITAS-B, Insomnia Treatment Acceptability Scale–Behavioral Subscale; ITAS-M, Insomnia Treatment Acceptability Scale–Medica-
tion Subscale; SF-8, Medical Outcomes Study SF-8 global health status measure; CES-D, Center for Epidemiologic Studies
Depression Scale, SE-S, Self-Efficacy for Sleep Scale; DBAS, Dysfunctional Beliefs about Sleep Scale; ISI, Insomnia Severity Index.
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variables (age, medication acceptability [ITAS-M],
health status [SF-8], depression [CES-D], self-effi-
cacy for sleep [SE-S], dysfunctional beliefs and at-
titudes about sleep [DBAS], and insomnia severity
[ISI]). There were no significant associations between
behavioral treatment acceptability and sociodemo-
graphic status. With regard to psychosocial predic-
tors, acceptability of medication treatment (ITAS-M;
r  0.259) and dysfunctional belief (DBAS; r 
0.234) scores were both significantly correlated
with behavioral treatment acceptability scores (P 
.001).
Linear regression models were examined to deter-
mine net predictors of behavioral treatment accept-
ability. Inclusion of demographic variables explained
0.2% of ITAS-B variance (r2  0.002) and was not
statistically or practically significant in a step-wise
regression analysis; hence these factors were not con-
sidered further. Interrelationships of psychosocial
predictors required further exploration. A simple lin-
ear regression was used to determine the contribution
of each psychosocial factor. Medication acceptability
had the strongest bivariate association with behavioral
acceptability. However, medication acceptability also
was strongly related to other psychosocial predictors.
Accordingly, regressionmodels without (Table 4) and
with (Table 4) medication acceptance were examined.
The model excluding medication preference ex-
plained 9.3% of the variance in ITAS-B scores. In this
model, both dysfunctional beliefs and self-efficacy for
sleep explained strong net associations with behav-
ioral acceptability (P  .001). Insomnia severity was
also significantly associated with behavioral treatment
acceptability at a P  .05 significance level. Medica-
tion acceptance emerged as the strongest single net
predictor of behavioral treatment acceptability, ex-
plaining 8.4% of variance in ITAS-B scores. When
Table 3. Correlations with Insomnia Treatment
















ITAS-M, Insomnia Treatment Acceptability Scale–Medication
Subscale; SF-8, Medical Outcomes Study SF-8 global health
status measure; CES-D, Center for Epidemiologic Studies De-
pression Scale, SE-S, Self-Efficacy for Sleep Scale; DBAS, Dys-
functional Beliefs about Sleep Scale; ISI, Insomnia Severity
Index.
Table 4. A: Initial Regression Analysis for Behavioral Treatment Acceptability and Regression Analysis for
Behavioral Treatment Acceptability Including Medication Acceptability
R2 F Adjusted R2  P
Initial regression analysis for BTA
Linear model 0.113 5.833 0.093
Dysfunction beliefs 0.319 .001
SE-S 0.006 .001
ISI 0.005 .05
Regression analysis for BTA including
medication acceptability
ITAS-M model 0.088 22.596 0.084 0.277 .001
Final model 0.135 12.074 0.124
Dysfunction beliefs 0.252 .002
SE-S 0.004 .01
ITAS-M 0.229 .001
The ISI, SF-8 and CES-D were included in the analysis but were excluded from the final model because of nonsignificant contribution
to overall predictive power.
BTA, behavioral treatment acceptability; ITAS-M, Insomnia Treatment Acceptability Scale–Medication Subscale; SE-S, Self-Efficacy
for Sleep Scale; ISI, Insomnia Severity Index.
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medication acceptance was included as a predictor,
insomnia severity was no longer a significant factor in
the model, possibly because of the significant corre-
lation between ITAS-M results and insomnia sever-
ity, as measured by the ISI (r 0.249; P .001). The
combination of preference for medication, dysfunc-
tional beliefs about sleep, and self-efficacy for sleep
created a best model at F(3, 235) 12.074 (P .001),
accounting for 12.45% of the construct variance. De-
pression scores and health status were included in
both models (Table 4) but made no significant con-
tribution to overall predictive power.
Discussion
This study was conducted to identify demographic
and clinical/psychosocial correlates of acceptance
of behavioral treatments for insomnia. Our results
do not reveal any demographic associations with
behavioral treatment acceptance. Acceptance of
medications emerged as the strongest net predic-
tor. Insomnia severity, depressive symptoms, and
concurrent poor health status were not predictive.
However, the presence of high self-efficacy for
sleep-inducing behavior and dysfunctional beliefs
and attitudes about sleep (anxiety over the per-
ceived consequences of poor sleep, lack of informa-
tion about insomnia causes and treatment, and un-
realistic expectations of treatment) were significant
net predictors of behavioral acceptance.
Together, these variables accounted for 12.45%
of variance in behavioral treatment acceptance.
Other unmeasured variables may explain behav-
ioral treatment acceptance, and full understanding
of acceptance determinants cannot be offered at
this time. Nonetheless, in psychosocial research,
wherein numerous factors influence behavior, be-
liefs, and preferences, variance accounted for at this
level is considered substantive.49
Lack of demographic associations indicates, first,
that there is no significant need to target disinterested
groups for education regarding the benefits of behav-
ioral treatments. In addition, neither educational at-
tainment nor race/ethnicity had associations with be-
havioral acceptance. Thus, lower education and
minority status—factors associated with resistance to
behavioral and psychological treatments in other con-
texts—did not predict resistance to (nonacceptance
of) behavioral insomnia treatments. Providers should
avoid stereotypic treatment decisions by assuming
disinterest based on sociodemographic attributes.
The strong net relationship between behavioral
and medication acceptance is perhaps a function of
insomnia severity, which is highly correlated with
medication preference. In other words, patients more
severely impacted by their lack of sleep may be more
open to both options or to the rapid relief that med-
ications can afford. This relationship also may reflect
the characteristics of patients seen in primary care
medical settings, who are accustomed to medical and
medication solutions for many problems. Acceptance
of both behavioral treatments andmedications is both
surprising and informative. The historic separation of
mind and body in health care can lead clinicians to
view behavioral and medication modalities as oppo-
sites and that interest in one implies disinterest in the
other. However, our findings indicate that patients
presenting with requests for quick relief from sleeping
pills, a typical primary care scenario, should not be
presumed to be unaccepting of the longer-term ad-
vantages offered by behavioral treatments.
Depression and concomitant poor health status
did not predict behavioral acceptance. Assessment
of depression and medical/medication contributors
remains a key part of insomnia assessment and
diagnosis but, based on these results, should not be
used to assess patient acceptance of treatment rec-
ommendations.
The finding that self-efficacy for sleep is related
to interest in behavioral treatments indicates that
self-efficacy should be enhanced if behavioral treat-
ments are to be accepted and successful. Thus,
self-efficacy should be examined during the course
of developing an insomnia treatment plan and fos-
tered, if necessary, using techniques such as moti-
vational interviewing.
The relationship between behavioral treatment ac-
ceptance and dysfunctional beliefs suggests that elic-
iting the latter might be used to identify persons who
are open to behavioral approaches. This screening
can be accomplished easily in practice during the
course of eliciting a history of the insomnia com-
plaint. Alternatively, the DBAS measure used in this
study could be used. A shorter, 16-item version re-
cently has been validated.50
Several potential limitations need to be acknowl-
edged in a discussion of these results. First, data were
collected at 3 separate sites. Comparison of results by
site reveals no observable differences, but unrecog-
nized biases may have impacted results. Second, bi-
ases resulting from misunderstanding of survey items
or erroneous or falsified responses may have impacted
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results. Third, incomplete reporting of ethnicity may
have obscured relationships between race and insom-
nia severity. Nonetheless, the study sample was pre-
dominantly women and African Americans, attributes
that may limit generalizability. On the other hand,
this predominantly African-American sample ad-
vances understanding of treatment preferences
among a group at risk for greater insomnia severity
and consequences.51 Fourth, the $10 reimbursement
for survey completion may have motivated persons
without insomnia and thus no true treatment prefer-
ences to inflate ISI scores to qualify. Fifth, the cross-
sectional design reveals associations but not cause and
effect between treatment acceptance and hypothe-
sized predictors. In addition, patients’ statements of
preference may not actually translate to following
through with a treatment option. Finally, despite the
significant predictive power of medication preference,
self-efficacy, and dysfunctional beliefs and attitudes
about sleep, these variables accounted for 12.45% of
variance in behavioral treatment acceptance. Other
unmeasured variables also are explanatory and should
be examined in future research. Such variables may
include anxiety or health beliefs. Quality of the rela-
tionship with the health care provider is another po-
tential explanatory factor because satisfaction with
communication predicts treatment adherence and
thus greater likelihood of efficacy.52
Conclusion
This study identifies acceptance of medication
treatment, self-efficacy of sleep-inducing behav-
iors, and the presence of dysfunctional beliefs and
attitudes about sleep as predictors of acceptance of
behavioral treatments for insomnia, although other
unmeasured factors are also important contribu-
tors. Compared with previous studies of treatment
preferences, which were conducted mainly among
patients who were engaged in behavioral treatment
trials, this study was conducted in primary care, to
which most insomnia patients present and where
there is not a priori interest in behavioral treat-
ments. Although our results are cross-sectional and
therefore preliminary, they are potentially relevant
to clinicians in several respects. First, providers
should not assume that patients who present with
requests for quick relief using sleeping pills are disin-
terested in behavioral treatments. Second, assessing
and facilitating self-efficacy for sleep-enhancing be-
havioral change potentially can improve readiness for
and acceptance of behavioral insomnia therapies. Fi-
nally, screening for dysfunctional beliefs and attitudes
about sleep can identify patients who have interest in
behavioral approaches. Future research using pro-
spective research designs, a broader range of explan-
atory variables is needed to confirm these findings
and to examine relationships to satisfaction with care,
improvement in sleep quality and insomnia severity,
and patient-centered clinical outcomes such as well-
being and daytime function.
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